Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas
| Autor: | Wania Mussio, Ioana Lancranjan, Ana Maria Judith Lengyel, José Gilberto H. Vieira, Paulo Mitsuru Imamura |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adenoma
Adult Male medicine.medical_specialty Adolescent medicine.medical_treatment Gastroenterology Injections Internal medicine Medicine Humans Pituitary Neoplasms Prolactinoma Prospective Studies Bromocriptine Baseline values Chemotherapy Analysis of Variance business.industry Tumor shrinkage Obstetrics and Gynecology Middle Aged medicine.disease Prolactin Surgery Long acting Reproductive Medicine Tolerability Delayed-Action Preparations Female Visual Fields business medicine.drug |
| Zdroj: | Fertility and sterility. 59(5) |
| ISSN: | 0015-0282 |
| Popis: | Objective To evaluate the efficacy and tolerability of Parlodel LAR (Sandoz, Basel, Switzerland), a long-acting injectable bromocriptine, in PRL-secreting macroadenomas. Design Eleven patients with macroprolactinomas were studied in an academic environment in an open and prospective protocol. Ten patients were followed for 6months and 8 for 1year. Fifty to 200mg IM of Parlodel LAR were administered every 28days. Results At the end of the 1st month, 64% of the patients had PRL suppression of >75% of baseline values. After 1year, 88% of the cases had PRL suppression of >90%. Persistent PRL normalization was seen in three cases. Tumor shrinkage was seen in 64% of the patients on day 5, in 73% on day 28, and in 90% after 6months of treatment. Early visual field improvement was seen in 83% of the cases. All patients had improvement of clinical symptoms. Conclusion Parlodel LAR is well tolerated and very effective in the long-term treatment of patients with PRL-secreting macroadenomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|